These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 21030991)
1. Deal watch: co-promotion deals: panacea or poison pill? Borshell N; Papp T Nat Rev Drug Discov; 2010 Nov; 9(11):831. PubMed ID: 21030991 [No Abstract] [Full Text] [Related]
2. Clinical trials in India: balancing economic opportunity with the public health context. Dandona L Natl Med J India; 2006; 19(2):57-9. PubMed ID: 16756189 [No Abstract] [Full Text] [Related]
4. Leaders worry that U.S. is losing edge on cancer clinical trials. Twombly R J Natl Cancer Inst; 2008 Sep; 100(17):1196-9. PubMed ID: 18728275 [No Abstract] [Full Text] [Related]
5. The path less costly. Huggett B Nat Biotechnol; 2010 Oct; 28(10):1018. PubMed ID: 20944585 [TBL] [Abstract][Full Text] [Related]
6. Garry Neil. Interview by Asher Mullard. Neil G Nat Rev Drug Discov; 2012 Nov; 11(11):826. PubMed ID: 23123934 [No Abstract] [Full Text] [Related]
7. Guinea-pigging: healthy human subjects for drug safety trials are in demand. But is it a living? Elliott C New Yorker; 2008 Jan; ():36-41. PubMed ID: 18265451 [No Abstract] [Full Text] [Related]
8. Trial watch: Trends in clinical trial design complexity. Getz KA; Campo RA Nat Rev Drug Discov; 2017 May; 16(5):307. PubMed ID: 28417986 [No Abstract] [Full Text] [Related]
9. Deal watch: Abbott and Neurocrine to develop promising endometriosis drug. Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671753 [No Abstract] [Full Text] [Related]
10. [Clinical research and pharmaceutical industry. A relationship with advantages and disadvantages]. ten Cate JW; Büller HR Ned Tijdschr Geneeskd; 1999 Jul; 143(30):1572-6. PubMed ID: 10443284 [TBL] [Abstract][Full Text] [Related]
12. The long and winding road. Nat Rev Drug Discov; 2005 Jun; 4(6):443. PubMed ID: 15959946 [No Abstract] [Full Text] [Related]
13. Deals landscape: notable deals in the pharmaceutical industry in the first quarter of 2008. Shumoogam J; Al-Shamahi A IDrugs; 2008 May; 11(5):351-5. PubMed ID: 18465677 [TBL] [Abstract][Full Text] [Related]
14. Charles Hugh-Jones. Interview by Asher Mullard. Hugh-Jones C Nat Rev Drug Discov; 2013 Dec; 12(12):900. PubMed ID: 24287774 [No Abstract] [Full Text] [Related]
15. Resurrection men dig through the drug graveyard: ARYx revives problem blockbuster drugs. Wolfson W Chem Biol; 2005 Nov; 12(11):1155-6. PubMed ID: 16298292 [No Abstract] [Full Text] [Related]
16. Deal watch: Ablynx and Merck Serono collaborate on next-generation antibody products. Nat Rev Drug Discov; 2008 Nov; 7(11):881. PubMed ID: 18974745 [No Abstract] [Full Text] [Related]
17. The quiet rise of the clinical contractor. Wadman M Nature; 2006 May; 441(7089):22-3. PubMed ID: 16672945 [No Abstract] [Full Text] [Related]
18. How pharmaceutical industry funding affects trial outcomes: causal structures and responses. Sismondo S Soc Sci Med; 2008 May; 66(9):1909-14. PubMed ID: 18299169 [TBL] [Abstract][Full Text] [Related]
19. Patients, physicians, and clinical trials: the other side of the coins. Abramson SB; Flexner C; Snyderman R; Dieterich DT; Korn D; Temple R; Sherwood L; Goldblatt D J Investig Med; 1999 Sep; 47(8):343-57. PubMed ID: 10510587 [No Abstract] [Full Text] [Related]
20. TransCelerate makes progress. Mullard A Nat Rev Drug Discov; 2017 Mar; 16(4):229. PubMed ID: 28356586 [No Abstract] [Full Text] [Related] [Next] [New Search]